Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

被引：0

作者：

Masatoshi Kudo

Takuji Okusaka

Kenta Motomura

Izumi Ohno

Manabu Morimoto

Satoru Seo

Yoshiyuki Wada

Shinpei Sato

Tatsuya Yamashita

Masayuki Furukawa

Takeshi Aramaki

Seijin Nadano

Kazuyoshi Ohkawa

Hirofumi Fujii

Toshihiro Kudo

Junji Furuse

Hiroki Takai

Gosuke Homma

Reigetsu Yoshikawa

Andrew X. Zhu

机构：

[1] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[2] National Cancer Center Hospital,Graduate School of Medicine

[3] Aso Iizuka Hospital,Graduate School of Medicine

[4] National Cancer Center Hospital East,Graduate School of Medicine

[5] Kanagawa Cancer Center,undefined

[6] Kyoto University,undefined

[7] National Hospital Organization Kyushu Medical Center,undefined

[8] Kyoundo Hospital,undefined

[9] Sasaki Institute,undefined

[10] Kanazawa University,undefined

[11] National Hospital Organization Kyushu Cancer Center,undefined

[12] Shizuoka Cancer Center Hospital,undefined

[13] National Hospital Organization Shikoku Cancer Center,undefined

[14] Osaka International Cancer Institute,undefined

[15] Jichi Medical University,undefined

[16] Osaka University,undefined

[17] Kyorin University Faculty of Medicine,undefined

[18] Eli Lilly Japan K.K.,undefined

[19] Massachusetts General Hospital Cancer Center,undefined

[20] Harvard Medical School,undefined

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Alpha-fetoprotein; Hepatocellular carcinoma; Japanese subanalysis; Ramucirumab; VEGFR2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 639

页数：12

共 50 条

[31] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Chau, Ian
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Poon, Ronnie
Pastorelli, Davide
Blanc, Jean-Frederic
Kudo, Masatoshi
Pfiffer, Tulio
Hatano, Etsuro
Chung, Hyun Cheol
Kopeckova, Katerina
Phelip, Jean-Marc
Brandi, Giovanni
Ohkawa, Shinichi
Li, Chung-Pin
Okusaka, Takuji
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew X.
BRITISH JOURNAL OF CANCER, 2018, 119 (01) : 19 - 26
[32] PATIENT-REPORTED OUTCOMES (PROS) WITH RAMUCIRUMAB VERSUS PLACEBO IN CHINESE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AND ELEVATED ALPHA-FETOPROTEIN FROM THE RANDOMIZED PHASE 3 REACH-2 STUDY
Chen, X.
Shao, G.
Bai, Y.
Gu, S.
Gu, K.
Zhang, Q.
Zhang, W.
Liu, J.
Zhou, L.
Qin, S.
VALUE IN HEALTH, 2022, 25 (12) : S19 - S20
[33] Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
Galle, Peter R.
Kudo, Masatoshi
Llovet, Josep M.
Finn, Richard S.
Karwal, Mark
Pezet, Denis
Kim, Tae-You
Yang, Tsai-Sheng
Zagonel, Vittorina
Tomasek, Jiri
Phelip, Jean Marc
Touchefeu, Yann
Koh, Su-Jin
Stirnimann, Guido
Wang, Chunxiao
Ogburn, Kenyon
Abada, Paolo
Widau, Ryan C.
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[34] SERIAL ALPHA-FETOPROTEIN ASSESSMENT AND SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB
Personeni, Nicola
Bozzarelli, Silvia
Giordano, Laura
Rimassa, Lorenza
Pressiani, Tiziana
Tronconi, Maria Chiara
Sclafani, Francesco
Carnaghi, Carlo
Santoro, Armando
ANNALS OF ONCOLOGY, 2009, 20
[35] Early decrease of alpha-fetoprotein predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma
Kuzuya, Teiji
Katano, Yoshiaki
Ishigami, Masatoshi
Hayashi, Kazuhiko
Honda, Takashi
Goto, Hidemi
HEPATOLOGY, 2012, 56 : 455A - 455A
[36] Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
Llovet, J.
Kudo, M.
Kang, Y-K.
Yen, C-J.
Finn, R. S.
Galle, P. R.
Assenat, E.
Motomura, K.
Okusaka, T.
Berg, T.
Hsu, C-H.
Ikeda, M.
Hsu, Y.
Liang, K.
Widau, R.
Schelman, W.
O'Brien, L.
Gao, L.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2019, 30 : 293 - +
[37] Early alpha-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Lee, Sangheun
Kim, Beom Kyung
Kim, Seung Up
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Han, Kwang-Hyub
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2015, 2 : 39 - +
[38] Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
Kang, Y-K.
Kudo, M.
Lim, H-Y.
Hsu, C-H.
Vogel, A.
Brandi, G.
Cheng, R.
Carton, I.
Abada, P.
Hsu, Y.
Zhu, A.
Yen, C-J.
ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
[39] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
Gerken, G.
Zhu, A.
Kang, Y-K
Yen, C-J
Finn, R.
Galle, P.
Llovet, J.
Assenat, E.
Brandi, G.
Lim, H. Y.
Pracht, M.
Rau, K-M
Merle, P.
Motomura, K.
Ohno, I
Daniele, B.
Shin, D. B.
Abada, P. B.
Hsu, Y.
Kudo, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 254
[40] A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Andrew, Zhu
Peter, Galle
Masatoshi, Kudo
Richard, Finn
Ling, Yang
Paolo, Abada
Josep, Llovet
ANNALS OF ONCOLOGY, 2016, 27 : 83 - 83

← 1 2 3 4 5 →